10th Oct 2013 08:02
LONDON (Alliance News) - Skyepharma PLC said Thursday that it expects revenues from the supply of its flutiform inhaler technology would be lower in the second-half of the year now that launch stocks have been supplied for many markets.
Revenues for the second-half of 2013 had benefited from several million US dollars received after the approval of flutiform in Japan, the company said. A further payment of EUR3 million will be payable when flutiform is launched in France, Skyepharma said, which it anticipates in 2014.
Skyepharma produces oral and inhalation drug delivery technologies; its product flutiform has been approved in 21 countries in Europe. Mundipharma is responsible for the development and commercialisation of flutiform in Europe and the rest of the world outside of Japan and the Americas. Mundipharma has said that uptake and sales of flutiform are in line with expectations, and it anticipates further launches during 2013 and 2014.
The company's partner Kyorin Pharmaceutical Company intends to launch the product in Japan as soon as possible, and Skyepharma anticipates a launch in the next few months.
Shares in Skyepharma were trading down 5.1% at 84.00 pence Thursday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
SKP.L